It was in 1976 when addressing a group of doctors, His Holiness Sri Jayendra Saraswathi, the Sankaracharya of the Kanchi Kamakoti Peetam spoke of the need to create a hospital with a missionary spirit. His words marked the beginning of a long journey to do God’s own work. On the command of His Holiness, Dr. Sengamedu Srinivasa Badrinath, along with a group of philanthropists founded a charitable not-for-profit eye hospital.

Sankara Nethralaya today has grown into a super specialty institution for ophthalmic care and receives patients from all over the country and abroad. It has gained international excellence and is acclaimed for its quality care and compassion. The Sankara Nethralaya family today has over 1400 individuals with one vision – to propagate the Nethralaya philosophy; the place of our work is an Alaya and Work will be our worship, which we shall do with sincerity, dedication and utmost love with a missionary spirit.

Contents

Guest Editorial: The Tale of Refractive Surgery
Prema Padmanabhan 19

Major Review: MicroRNA: Potential Therapeutics of Eye Cancer
Swathi Lingam 20

Tips and Tricks: Tips and Pearls in Corneal Examination
A. Shweta, B. Sumanta and A. Bharti 23

Case Report: Spontaneous Resolution of Congenital Glaucoma
L. Vijaya and M. Baskaran 25

Case Report: Unilateral Full Thickness Macular Hole in Association with Serpiginous Choroiditis
P. Ranganathan and J. Biswas 27

Residents’ Corner: Intravitreal Medications in Uveitis
A. Maheshwari 29

Optics & Refraction: Cycloplegic Refraction in Children
L. Jayalakshmi, N. Kalpa and R. Srikanth 30

Inquiries or comments may be mailed to the editor at insighteditor@snmail.org

Cover photo: Mr. M.S. Krishna, Senior photographer, Department of Ophthalmic Photography, Sankara Nethralaya
The Tale of Refractive Surgery

Prema Padmanabhan

"It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the season of Light, it was the season of Darkness, it was the spring of Hope, it was the winter of Despair..." This could well be a Dickensonian summary of "The Tale of Refractive Surgery".

It would be no exaggeration to say that no other field in Ophthalmology has seen so many changes in so short a time as Refractive Surgery has in the last 25 years. Once considered an experimental hobby, it has gradually gained a level of acceptance even among its most vocal critics. It has, in this short span of time, become the most commonly performed elective procedure done on the human body. A meta-analysis of the USFDA approved Lasik device studies across the globe 8 years ago, found that 96% of patients reported satisfaction. With improved technology that is used today, that figure would be even higher. This can only mean that refractive surgery has met the physical, emotional and financial expectations of its clientale.

Ametropia is now correctable by a myriad surgical techniques—each more clever in design and imaginative in name than the other. Although today the term “Refractive Surgery” is almost synonymous with Laser Refractive Surgery, there are several non-laser techniques as well that a surgeon can choose from. The multiple procedures and their acronyms make for a colorful landscape, but they could all fall into one of four broad categories—incisional (RK being the most notorious and AK the most handy), thermal (like CK that was born only to be buried), lamellar (which began with ALK but soon gave way to Laser Refractive Surgery in all its forms) and intraocular surgery (IOLs that may or may not replace the crystalline lens). With so many choices, the challenge, in Refractive Surgery, lies in choosing the appropriate procedure for each eye. Sometimes, however, the bigger challenge lies in determining the appropriateness of refractive surgery itself for the eye. Failure to do so has resulted in catastrophies. But the more genuine difficulty in “smelling the rat” has often resulted in the landmine blowing into the surgeon’s face. Iatrogenic keratectasia is probably the most feared—and embarrassing—example of a complication resulting, most often, from improper patient selection. There are more types of diagnostic gadgets that the surgeon can now use for patient screening and selection. The proper interpretation of the ‘displays’ on some of them can be more confusing than is apparent and calls for an understanding of its working principle and equally, of its limitations.

When the right patient and the most suited procedure are chosen, every patient deserves a detailed counseling. Just as it is important for the surgeon to understand the needs and expectations of the patient, it is no less important for the patient to understand the possibilities and limitations of the procedure. Disclosing the unvarnished truth about possible side-effects is a moral responsibility, we owe our patients and sets the patients expectations to more realistic levels.

The introduction of the Femtosecond laser has raised the bar in terms of precision and has opened new windows of possibilities. The femtosecond laser allows the surgeon to choose the diameter, shape, thickness, depth, angle and location of corneal flaps and hinges and makes customized laser refractive surgery more achievable than it earlier was. Extending the versatility of the Femtosecond laser to perform flapless refractive surgery by extracting a lenticule fashioned entirely by the femtosecond laser, may be an important milestone in the journey of Refractive surgery. By avoiding flap-related complications, it would enhance the safety of the procedure, but we do need to wait for the results of current clinical trials.

The possibilities are mind-boggling. But unless each new procedure passes the test of scientific scrutiny and critical analysis, unless well-designed studies with clear documentation are healthily discussed, unless there is an honest self-reporting of failures and complications, we would be guilty of creating an ophthalmic Frankenstein. The complexity of the optical design of the human eye is even more mind-boggling. Novel ideas, brilliant technology, deft surgery have not been able to improve the quality of the biological optical system of the human eye, at least until now. Even as we applaud human achievement and serendipidity, let us pause for a movement in silent reverence for all that the cornea has given and forgiven. 

How to cite this article Prema P. The Tale of Refractive Surgery, Sci J Med & Vis Res Foun 2014;XXXII:19.
MicroRNA: Potential Therapeutics of Eye Cancer

Swathi Lingam

MicroRNAs (miRNAs) are small single stranded nucleotides that are ~22 base pairs long. They were first identified in Caenorhabditis elegans. Functionally, they are involved in post transcriptional regulation of gene expression by binding to the 3’ untranslated regions of transcribed mRNA. Mature miRNA also interact with Argonaute proteins, and are induced into the RNA induced silencing complex which is involved in gene silencing. Gene silencing occurs when a mutation causes the gene to lose its function. Recently, miRNAs have been found to be associated with diseases such as cardiovascular disease, metabolic diseases and cancer.

Retinoblastoma

Studying the role of miRNA in retinoblastoma could be very important since it has a potential for development into a treatment strategy. The earliest report of an association between miRNA and retinoblastoma was made in the year 2009 by Dalgard et al. They investigated the role of miR-34a and were able to identify its differential expression in retinoblastoma cell lines, and comprehensively proved that it acts as a tumor suppressor miRNA. miR-34a is associated with p53, a known tumor suppressor gene, whose pathway is inactivated in a subset of retinoblastoma tumors. As a result of their study, it was possible to hypothesize that increasing miR-34a expression can possibly activate the p53 tumor suppression pathway, and ultimately lead to cancer cell apoptosis thus paving way for a possible future miRNA-based therapy of retinoblastoma. Just like miR-34a, miR-449a and miR-449b are also tumor suppressor miRNA. Their over expression in retinoblastoma cell lines has been associated with decreased cell proliferation and increased apoptosis. Since miRNAs are regulators of gene expression, their interactions with genes involved in retinoblastoma have been studied. One such study identified miR-365b-3p, an miRNA that is down regulated in retinoblastoma, and interacts with PAX6, a gene that is involved in retinoblastoma development. It was found that PAX6 expression was inhibited by this miRNA, and that it functioned as a tumor suppressor.

Cancer associated miRNAs are of two types; those associated with oncogenes (called onco-miRNAs or oncomirs), and those linked to tumor suppressor genes, as described in the previous section.

The miR-17-92 cluster is a cluster of oncogene associated miRNA, which has been shown to be involved in retinoblastoma. The first study that indicated this association was carried out by Conkrite et al. in the year 2011. They were able to prove that Rb gene deletion leads to an increase in the levels of the polycystrionic miR-17-92 cluster. The expression of these miRNA appeared to be directly proportional to the rate of disease progression in vitro, and in an Rb mouse model. Epithelial cell adhesion molecule (EpCAM) is a glycoprotein that is expressed only in epithelial cells and epithelial neoplasms. In retinoblastoma, it was identified as a possible cell surface marker, and its regulation of the miR-17-92 cluster was studied. It was found that the miR-17-92 cluster can be positively correlated to EpCAM expression, and is involved in retinoblastoma progression in vitro. This is a promising result since this correlation can be used as a potential target for retinoblastoma therapy. If EpCAM is knocked down, it will lead to the reduction of miR-17-92, which in turn can cause tumor regression. This effect was observed in vitro, but has to be studied in animal models before it can be taken to the clinical trial level. These tumor suppressor and onco-miRNA appear to be useful targets for future retinoblastoma therapy. miRNA-based therapy can be used independently or in conjunction with current forms of therapy to improve the quality of life for a retinoblastoma patient.

Identification of miRNA that are differentially expressed in retinoblastoma is possible using microarray technology. This helps in the identification of novel miRNA, consequently increasing the number of miRNA that can be targeted for

<table>
<thead>
<tr>
<th>miRNAs associated with oncogenes</th>
<th>miRNAs associated with tumor suppressor genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examples</td>
<td>miR-17-92 cluster</td>
</tr>
<tr>
<td>Role in eye cancer (experimental)</td>
<td>Progression of retinoblastoma by overexpression due to Rb gene deletion</td>
</tr>
</tbody>
</table>
therapy. On comparing 12 retinoblastoma tumors to 3 normal retinas, Martin et al. were able to identify 41 differentially expressed miRNA in retinoblastoma tissue.

miRNA released into the serum are also emerging as possible biomarkers of disease. In an effort to identify serum biomarkers for retinoblastoma, microarray technology was utilized, and yielded 45 differentially expressed miRNA in retinoblastoma serum compared with normal age matched serum. Of these, 21 were upregulated, and 24 were down regulated. It was also possible to identify the gene targets of these miRNA. This information is invaluable as it opens many doors for research into serum biomarkers for retinoblastoma.

**Uveal melanoma**

Melanoma is a cancer of pigment cells (melanocytes). In the eye, this cancer originates from the melanocytes in the uvea (iris, ciliary body and choroid). The treatments of choice for uveal melanoma are local radiation using iodine 125 plaques, and in extreme cases, eyeball removal. miRNAs are also being investigated as possible therapeutic targets for uveal melanoma. miR-34a was previously correlated with tumor suppression in retinoblastoma. Two members of the same family, namely miR-34b/c have been associated with suppression of uveal melanoma migration and cell proliferation. It was found that they act as tumor suppressors through the down regulation of several genes involved in the cell cycle. Just as in retinoblastoma, over expression of these miRNA can help in disease regression.

Nuclear factor kappa B (NF-κB) is a transcription factor family that is involved in cell proliferation, angiogenesis and tumor metastasis. NF-κB1, a member of this family is a target of miR-9, which is associated with tumor suppression in uveal melanoma. Liu et al. showed that expression of miR-9 can be associated with tumor suppression through its interaction with NF-κB1. This same group was also able to show that miR-9 inhibits genes in the NF-κB pathway, such as vascular endothelial growth factor A, MMP-2 and MMP-9 (matrix metalloproteinase). Such an association makes miR-9 a suitable target for treatment of uveal melanoma.

Another tumor suppressor miRNA found to inhibit uveal melanoma progression in vitro is miR-124a. Yan et al. were able to prove that on transfecting miR-124a into uveal melanoma cell lines, there was increased cell cycle arrest and apoptosis. Furthermore, they were able to identify that miR-124a works by targeting the 3’ UTR regions of MITF, BCL2 and Cyclin D2, which are involved in tumor progression. The expression of miR-124a is dependent on p53 expression, which is a known tumor suppressor gene.

miR-124a is yet another tumor suppressor that is involved in uveal melanoma tumor suppression. In an in vitro study, transfecting uveal melanoma cell lines with miR-124a showed a significant decrease in tumor cell growth, invasion and migration. In an in vivo study, tumor suppression was observed. It was found to be epigenetically regulated during melanoma progression, leading to its down regulation.

**Conclusion**

Since the discovery of miRNA little over a decade ago, the fact that they are associated with disease conditions has opened up an entire area of research. There are exciting possibilities for disease treatment and early diagnosis by using miRNA as biomarkers. This approach is especially important in cancer, where associated miRNA are of two types, oncomiRNA and tumor suppressor miRNA. By regulating their target genes, oncomiRNA promote tumor progression, whereas tumor suppressor miRNA have the opposite function.

In the section above, several tumor suppressor and oncomiRNA involved in retinoblastoma and uveal melanoma have been described. Their role in tumor progression, their possible tumor biology, and what this means for treatment have been hypothesized. Theoretically, if an oncomiRNA is down regulated, and a tumor suppressor miRNA is upregulated, tumor progression should be arrested. However, the process is never that straightforward. The pathways involved in tumor progression are complex, and there are several regulatory mechanisms. Also, this cancer related miRNA have many gene targets, and just turning them on and off may not necessarily have the expected effect on tumor progression. What is required is a cumulative approach involving manipulation of onco genes and tumor suppressor genes and controlling expression of tumor suppressor miRNA, oncomiRNA and their target genes. Once a successful combination leading to tumor progression arrest/cancer cell apoptosis has been identified, it has to show a significant effect in cell lines, in animal models and lastly, human clinical trials before it can be used as a form of therapy.

The use of circulating miRNA in blood plasma and serum as biomarkers of early stage disease, however, is a more achievable target. Since cancer miRNAs are indicators of the disease, accurately quantifying their expression levels can throw light on the presence of the disease, and the stage of the cancer. This is a very important discovery as it can eliminate the need for invasive methods of diagnosis. This is important in tumors such as retinoblastoma where tumor sampling is not possible.

In conclusion, miRNA-based therapy and diagnosis could be the future in the fight against cancer. miRNA and gene manipulation will have
to be used in conjunction with existing treatment strategies, and this will be a potent combination.

References


How to cite this article Swathi L. MicroRNA: Potential Therapeutics of Eye Cancer, Sci J Med & Vis Res Foun 2014; XXXII:20–22.
Examination of an eye is like a jigsaw puzzle. Every symptom and sign gives you a clue to complete your puzzle. A complete examination would include a detailed history, visual acuity, slit lamp examination, intraocular pressure measurements, fundus evaluation and ancillary tests like staining and schirmer.

Let us go through some common corneal signs and see what each one tells us, however, it is beyond the scope of this article to cover all diseases.

1. Superficial punctuate keratitis:

2. Filamentary keratitis: filaments appear as mucoid deposits adherent to the corneal surface.

3. Epithelial defect: a breach in the continuity of the epithelium is called an epithelial defect.

4. Ulcer: an epithelial defect associated with inflammation. An ulcer has varied presentations. But based on its location, edges, shape, depth of involvement associated hypopyon a fair idea of etiology can be made.

<table>
<thead>
<tr>
<th>Sign</th>
<th>Symptoms</th>
<th>Differential diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimally raised superficial punctuate staining pattern</td>
<td>Irritation, FB sensation, Photophobia</td>
<td>Lids: concretions, granuloma, papillae, foreign body, blepharitis, meibomian gland disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Conjunctiva: conjunctivochalasis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ocular surface conditions: dry eye, allergic or infective keratoconjunctivitis, viral keratitis contact lens induced, toxic medicamentosa</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Disease</th>
<th>Distribution of filaments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral</td>
<td>Herpes simplex</td>
<td>Usually single filament</td>
</tr>
<tr>
<td>Trauma</td>
<td>Corneal abrasion</td>
<td>Usually single layer</td>
</tr>
<tr>
<td>Surgery</td>
<td>Multiple surgeries</td>
<td>Diffuse</td>
</tr>
<tr>
<td>Others</td>
<td>Dry eye, Superior limbic keratoconjunctivitis, Neurotrophic keratopathy, Toxic medicamentosa</td>
<td>Interalpebral, Upper one third of cornea, Lower one third of cornea</td>
</tr>
</tbody>
</table>

Dendritic: herpes simplex, herpes zoster, healing epithelial defect

Ring ulcer: fungal, acanthamoeba, pseudomonas, severe corneal burn, corneal foreign body
5. Scar: final outcome of any inflammatory lesion. Depending on the layer of corneal involvement it is three types nebular, macular and leucomatous.

6. Edema: due to accumulation of fluid in corneal stroma and/or epithelium.

7. Vascularization:

<table>
<thead>
<tr>
<th>Types of vascularization</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superficial</td>
<td>LSCD, CI wear, blepharitis, chronic inflammation</td>
</tr>
<tr>
<td>Deep</td>
<td>Interstitial keratitis, viral keratitis</td>
</tr>
</tbody>
</table>

Sign | Symptom
--- | ---
White opaque, no epithelial defect, well-defined margins, quiet eye | Minimal photophobia no pain or watering

Etiology | Presentation
--- | ---
Primary endothelial failure (Fuchs, CHED) | Primarily stromal, diffuse progressive
Secondary endothelial failure (viral keratitis, trauma) | Primarily stromal, focal or diffuse
Elevated IOP with normal endothelium | Primarily epithelial, microcytic edema

Further reading
1. Krachmer Jay H, Mannis Mark J, Holland Edward J. Cornea, vol 1; Examining and imaging the cornea and external eye.

How to cite this article Shweta A, Sumanta B, Bharti A. Tips and Pearls in Corneal Examination, Sci Med & Vis Res Foun 2014;XXXII:23–24.
Spontaneous Resolution of Congenital Glaucoma

L Vijaya and M Baskaran

Abstract
To report clinical features in five eyes of three cases with spontaneously resolved congenital glaucoma. All eyes showed megalocornea, deep anterior chambers and refractive status of either high myopia or astigmatism. Gonioscopy revealed high anterior insertion of iris with iris processes. Three eyes showed Haab's striae, two eyes showed features of Reiger's anomaly. Repeated intraocular pressure measurements were in normal range. Congenital glaucoma can resolve on its own leaving behind features suggestive of previous raised intraocular pressure.

Introduction
Congenital glaucoma occurs in one out of 10,000 births and prevalence is 0.01–0.04% of general ophthalmic patients.1 Spontaneous resolution of such congenital glaucoma has rarely been reported in the literature.1,2 Most of the times such cases have been diagnosed on a presumptive basis, that is, from subsequent findings rather than actual documentation of resolution of glaucoma.3 We report five eyes of three patients where in typical clinical sings of congenital glaucoma were seen with consistent normal intraocular pressure indicating the spontaneously resolved condition. None of them had surgery or medical treatment for raised intraocular pressure prior to presentation.

Case 1: A 15-year old male with history of defective vision in left eye and enucleation of right eye at the age of 7 years. Examination of left eye revealed visual acuity of 6/9 with a refractive correction of +1.00 diopter sphere and −5.00 diopter cylinder at axis of 90°. Slit lamp biomicroscopy showed megalocornea, Haab’s striae and a deep anterior chamber. Gonioscopy revealed anterior insertion of iris with prominent iris processes. Intraocular pressure was 17 mmHg with applanation tonometer. Optic nerve head evaluation with 90 diopter lens using slit lamp biomicroscopy showed cup disc ratio of 0.6:1 with healthy neural rim.

Case 2: A 9-year old female presented with a history of defective vision in both eyes. Examination revealed visual acuity of 3/36 with −7.00 diopter sphere in right eye 6/36 with −14.00 diopter sphere in the left eye. Slit lamp biomicroscopy showed megalocornea, deep anterior chamber and corectopia. Applanation tonometry showed intraocular pressure of 17 and 18 mmHg in the right and left eyes, respectively.

Case 3: A 3-year old presented with a history of blunt trauma to the left eye 2 months back. Examination showed that the child was able to fixate and follow the objects well with right eye while there was no perception of light in the left eye. The refractive error in the right eye was −2.00 diopters sphere with −2.00 diopter cylinder at axis of 20°. Slit lamp biomicroscopy showed megalocornea, Haab’s Striae (Fig. 1) and a deep anterior chamber in both eyes. In addition, the left eye showed complicated cataract. Gonioscopy revealed anterior insertion of iris with iris processes (Fig. 2) the right eye optic nerve head showed glaucomatous cupping and ultrasonography of the left eye revealed total retinal detachment.

Megalocornea, Haab’s striae with axial myopia or astigmatism are suggestive of previously raised intraocular pressure. Breaks in Descemet’s membrane (Haab’s Striae) from increased intraocular pressure rarely occur after age 3.4 This suggests all five eyes possibly had raised intraocular pressure before 3 years of age. Lockie and Elder2 reported three cases of documented spontaneous resolution of glaucoma, out of the three cases one case was seen before and after disappearance of glaucoma. Their series did not mention about gonioscopic features. Primary infantile glaucoma has very characteristic angel features.1 The presence or absence of congenital glaucoma can be judged

Figure 1. Case 3: external photography of the right eye showing Haab’s Striae.
from non-gonioscopic signs and symptoms, but gonioscopy confirms the diagnosis of congenital glaucoma. In our series, all eyes showed anterior insertion of iris, which eliminates possibility of secondary glaucoma during childhood and confirms the diagnosis of congenital glaucoma. The mechanism of spontaneous resolution is unclear; it is thought to be due to continuous development of angle even after birth with disappearance of the embryological tissue that causes precanalicular obstruction. Spontaneous resolution of congenital glaucoma is definite entity, though rare.

References


Figure 2. Case 3: gonioscopic photography of the right eye showing anterior insertion of iris.
Unilateral Full Thickness Macular Hole in Association with Serpiginous Choroiditis

P Ranganathan and J Biswas

Introduction
Serpiginous choroiditis is a bilateral chronic progressive and recurrent disease of unknown etiology affecting the retinal pigment epithelium, choriocapillaries and choroid. Macular serpiginous choroiditis is a variant of serpiginous choroiditis. Macular hole is extremely rare in serpiginous choroiditis. We report a case of unilateral serpiginous choroiditis with macular hole. This is the first case of macular hole in serpiginous choroiditis reported in Indian literature to the best of our knowledge.

Case report
A 20-year old female patient from Tamil Nadu presented to us with chief complaint of blurring of vision and floaters since 3 months in right eye which was gradual in onset and progressive. She was diagnosed as right eye panuveitis 3 months ago elsewhere and was referred to us.

On examination her best corrected vision in right eye was 3/60, N36, left eye 6/5, N6. Her extraocular movements were normal. On slit lamp examination her right eye had vitreous cells 1+, left eye was normal. Fundus examination in right eye showed macular serpiginous choroiditis with thick epiretinal membrane. Left eye was normal. Optical coherence tomography was shown in Fig. 3.

Her laboratory tests were normal except for Quantiferon Gold TB test positive. She was started on oral steroid based on her weight and anti-tuberculosis treatment. On 1 month follow up her vision remained the same and she was complaining of more blurring of vision than the last visit. Her best corrected visual acuity in right eye was 3/60, N36. Left eye 6/5, N6.

On slit lamp examination anterior segment both eyes normal except right eye has vitreous cells (1+). Fundus examination revealed right eye healed serpiginous choroiditis with macular hole.

Figure 1. Fundus photograph showing active macular serpiginous choroiditis.

Figure 2. Fundus fluorescein angiogram shows active serpiginous choroiditis with hyperfluorescence border and central area of hypofluorescence.

Figure 3. Optical coherence tomography showing vitreomacular traction and epiretinal membrane (at first time presentation).
Left eye within normal limits. Optical coherence tomography is shown in Fig. 4. She was diagnosed as right eye healed seriginous macular choroiditis with full thickness macular hole. Pars plana vitrectomy, membrane peeling, gas tamponade done to right eye. Her postoperative vision was 6/60, N36. There was incompletely closed macular hole.

**Discussion**

Macular hole is not common in uveitis except in intermediate uveitis (pars planitis). It has been reported also in toxoplasmic retinochoroiditis and cat scratch disease. The cause of macular hole is not clear in choroiditis. In our case, probably there is persistent inflammation leading to vitreomacular traction causing macular hole. There was mild inflammation of the vitreous in our case (vitreous cells 1+). Other possibility is vitreomacular traction caused by the epiretinal membrane. Gregory et al. reported one case of bilateral macular hole in serpiginous choroiditis. In their patient, vitritis during recurrence may have caused irregular contraction of the premacular cortical vitreous. The absence of an operculum suggests centrifugal photoreceptor displacement by tangential vitreous traction. ERM contraction is another possible source of tangential traction in their case. Management in of macular hole is vitrectomy, internal limiting membrane peeling and gas tamponade. Visual prognosis is guarded in spite of successful surgery.

**References**


Intravitreal Medications in Uveitis

A Maheshwari

Correspondence to: Abhilasha Maheshwari, Post Graduate Trainee, Sankara Nethralaya, 18, College Road, Chennai 600006, India. E-mail: dimension.abhi@gmail.com

Intravitreal medications used in Uveitis

**Infectious**
- Intravitreal injections
- Intravitreal implants

**Noninfectious**
- Intravitreal injections
- Intravitreal implants

**Clindamycin:** 1mg/0.1ml
**Gancyclovir:**
  - *Induction dose:* 2mg/0.1ml, 2 times /week for 3 weeks
  - *Maintenance:* 2mg/0.1ml, once a week
**Fosarnet:** 1.2mg/0.05ml twice weekly for three weeks
**Fomiviren:**
  - *Induction:* 330 mcg once every 2 weeks
  - *Maintenance:* 330 mcg once every 1 month
**Cidofovir:**
  - *Induction:* 20 µg
  - *Maintenance:* repeat every five to six weeks

**Gancyclovir (VITRASERT):**
- 4.5 mg in 2.5 mm pellet releases 1mcg/hr for 8 months. (Intravit conc: 4.1 mcg/ml)

**Immunosuppressants:**
- Methotrexate: 400 mcg / 0.1ml
- Cyclosporine: 100mcg /0.1ml
- Steroids: Various doses like 352mcg, 440mcg /mL, 880 mcg/mL are under trial.

**Fluconazole acetamide (RETISET):**
- 0.59 mg pellet releases 0.6 mcg/day gradually decreasing to 0.3-0.4 mcg/day for total of 30 months

**Dexamethasone:**
- Sustained release
- Device (Osusted): 0.7 mg and 0.35 mg, gradually releases 0.3-0.4 µg/day dexamethasone in to the vitreous.

**Biologic response modifiers:**
- Adalimumab: 1.5 mg/0.03 ml
- Infliximab: 1.5 mg / 0.15 ml
Cycloplegic Refraction in Children

L Jayalakshmi¹, N Kalpa¹,² and R Srikanth²

Introduction
Refraction is a procedure to assess the refractive errors of the eye. In static retinoscopy, the patient is asked to fixate a distance target (4–6 m) thereby relaxing the accommodation and retinoscopy is performed. In children, maintaining distance fixation can be difficult and thus can cause fluctuations and inaccurate refraction. Control of accommodation is usually achieved by the use of pharmacological agents (cycloplegics) such as cyclopentolate, atropine, homatropine and tropicamide. Studies¹–² have proven that the human ciliary muscle carry muscarinic, angiotensin receptors and P2-adrenoceptors. Cycloplegic agents are anticholinergic and block the muscarinic action of acetylcholine. This inhibits cholinergic stimulation of the iris sphincter muscle and ciliary muscle, causing pupillary dilation (mydriasis) and cycloplegia (arresting accommodation).

In children, cycloplegic refraction is done to accurately assess the refractive power of the eye. Cycloplegic refraction³ involves determination of the refractive error when the patient’s accommodation is partially or totally paralyzed using a cycloplegic agent.

Indications for cycloplegic refraction

- Refractive errors
  - To assess the refractive power of the eye in children (myopia, hyperopia and astigmatism).
  - Poor co-operation/fixation during refraction.
  - Fluctuations in the refractive error while performing dry retinoscopy.
  - Vision not correlating with the dry refraction.
  - To rule out latent hyperopia.
  - Refractive surgery—to assess the refractive error accurately and rule out latent component.

- Accommodative anomalies
  - Asthenopia, headache or other symptoms due to accommodative problems such as amplitude of accommodation, dynamic retinoscopy, infacility, insufficiency etc.
  - Pseudomyopia/accommodative spasm—to assess the accurate refractive error and as a treatment to break the spasm

- Amblyopia
  - Penalization—especially atropine is given to the sound eye to blur the vision and training the use of amblyopic eye (PEDIG-ATS³–⁶ atropine penalization and patching achieve similar results in improvement in moderate amblyopia).

- Strabismus
  - All the types of squint especially accommodative and partially accommodative esotropia.

- Media opacities
  - Corneal/lenticular opacities obscuring the visual axis but which show a clear peripheral area on dilatation with a mydriatic eye drop (commonly tropicamide or homatropine) to delay surgical intervention when necessary.

- Uveitis
  - To relieve pain and prevent the formation of synechiae.

- Post-operatively
  - To manage post-operative inflammations.

- Malingering

Common cycloplegic agents used by eye care practitioners³
Table 1 describes the cycloplegic and mydriatic effect of different cycloplegic agents.

Post-cycloplegia

- General effects
  - Long lasting mydriasis.
  - Muscle balance and near point testing cannot be performed.
  - Photophobia/difficulty seeing bright lights.
  - Local and systemic toxic and allergic side effects are potentially significant.

- Effects of poor cycloplegia
  - Fluctuations in refractive error while performing retinoscopy and error in refraction.

- How to check cycloplegic effect
  - Pupillary reaction to light.
  - Blurred near vision with receded near point of accommodation.
Variation of refractive error while fixating at a distance and near target.

**Methods of performing cycloplegic refraction**

- **Retinoscopy**
  Retinoscopy (also called skiascopy) is a technique to objectively determine the refractive error of the eye using a retinoscope. In children, it is challenging to perform cycloplegic refraction especially in infants. Infants are engaged showing different colored target (e.g., even mobile phones with interesting cartoons and videos) as a fixation target and retinoscopy is performed holding loose lenses in front of the eye as shown in Fig. 1.

- **Autorefractometer**
  Autorefractometers (Fig. 2) have become more important in recent years because of the busy schedule of the eye care practitioners. Studies have proved that there is no significant difference in cycloplegic refraction between manual retinoscopy method and autorefractometer whereas difference was noted with non cycloplegic refraction between them.

- **Open-field autorefractometer**
  Open-field autorefractometer (Fig. 3) allows the patient to fixate at any distance and refractive error can be determined. Studies report that it has been validated for measuring refraction reliably in young adult population.

### Table 1.

<table>
<thead>
<tr>
<th>Agent</th>
<th>Strength (percentage)</th>
<th>Mydriasis</th>
<th>Cycloplegia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Maximum (min)</td>
<td>Recovery time</td>
</tr>
<tr>
<td>Phenylephrine</td>
<td>2.5</td>
<td>20</td>
<td>2–3 h</td>
</tr>
<tr>
<td>Tropicamide</td>
<td>0.5, 1</td>
<td>20–40</td>
<td>2–6 h</td>
</tr>
<tr>
<td>Cyclopentolate</td>
<td>0.5, 1, 2</td>
<td>30–60</td>
<td>6–24 h</td>
</tr>
<tr>
<td>Homatropine</td>
<td>2, 5</td>
<td>40–90</td>
<td>1–3 days</td>
</tr>
<tr>
<td>Atropine</td>
<td>0.5, 1</td>
<td>30–60</td>
<td>7–14 days</td>
</tr>
</tbody>
</table>

**Figure 1.** Retinoscopy being performed by an optometrist.

**Figure 2.** Autorefractometer.

**Figure 3.** Open-field autorefractometer.
and it can measure both static and dynamic accommodation. It can be used in children, giving them attractive distance targets to assess the refractive error.

- Photoscreener\textsuperscript{10–15}

Photoscreening uses a camera to capture the image of a child’s eye in un-dilated or dilated state. These images are analyzed using special software to estimate the refractive error and this technique is termed as photorefraction. Commonly available photoscreeners are iScreen and Plusoptiks\textsuperscript{TM}.

Comparing different methods

- Manual retinoscopy still holds to be the gold standard method to assess the refractive error in children.

- Many studies have compared the use of the above-mentioned methods. There is no significant difference in these methods under cycloplegia. However, open field autorefractometer gives low hyperopic readings before and after cycloplegia as compared with closed field autorefractometer which overestimates myopia and underestimates actual hyperopia (instrumental myopia—near fixation).

Conclusion

Cycloplegia in children though is mainly used to determine the refractive error; it is also indicated for other purposes. Manual retinoscopy is still the gold standard method and accurate technique to determine refractive status of children. The refraction skills of an eye care practitioner especially in pediatric population are important and challenging. In children, we mostly depend on cycloplegic refraction to determine the accurate refractive error and prescribe correction.

References


How to cite this article

The Sankara Nethralaya Academy
(Unit of Medical Research Foundation),
No 9 Vanagaram – Ambattur Road, Ayanambakkam, Chennai – 600 095
www.thesnacademy.ac.in

The Sankara Nethralaya Academy (TSNA) is education arm of Sankara Nethralaya (a unit of Medical Research foundation)
TSNA is avowed to employ a system of educating people in a community or society, arts, and science colleges, imparting knowledge through instruction courses, training classes, and usher in newer training/teaching methodologies including the use of IT. The objective is to teach courses that deal with A to Z in healthcare services.

TSNA offers career oriented programs in the field of allied healthcare and Hospital administration. Our allied health science courses are run in collaboration with The Tamil Nadu Dr MGR medical University. The programs have been designed to meet the growing demand for the well trained health care professionals.

### Key Features of our Academy are
- Modern air conditioned classroom built for aesthetic comfort
- Library facility
- Interactive classroom session with eminent faculties
- Hostel facility available on request
- Audio Video classroom facility
- Hi speed internet and Computer lab with latest systems.
- No Capitation / Donation Fees
- Transportation facilities,
- Nominal Fee structure
- Flexible fee payment option (Installments)
- Faculty and student collaborative projects
- Education loan through City Union Bank (for applicable courses)
- Tie up with Multi Speciality Hospital

The following courses are offered by our SN Academy are:

<table>
<thead>
<tr>
<th>S No</th>
<th>Degree and Diploma Courses</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Diploma in Operation Theatre &amp; Anaesthesia Technology.</td>
</tr>
<tr>
<td>2</td>
<td>Diploma in Ophthalmic Nursing Asst (ONA)</td>
</tr>
<tr>
<td>3</td>
<td>Diploma in Refraction and Dispensing</td>
</tr>
<tr>
<td>4</td>
<td>BSc Medical Laboratory Technology</td>
</tr>
<tr>
<td>5</td>
<td>MS Medical Laboratory Technology</td>
</tr>
<tr>
<td>6</td>
<td>MBA in Hospital and Health System Management.</td>
</tr>
</tbody>
</table>

### Short term / Certificate Courses

<table>
<thead>
<tr>
<th>S No</th>
<th>Course details like:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Affiliation / Association / Eligibility Criteria / Fees Structures</td>
</tr>
<tr>
<td>2</td>
<td>to be referred our website: <a href="http://www.thesnacademy.ac.in">www.thesnacademy.ac.in</a></td>
</tr>
<tr>
<td>3</td>
<td>or</td>
</tr>
<tr>
<td>4</td>
<td>Write to:</td>
</tr>
<tr>
<td>5</td>
<td>A Mahalingam</td>
</tr>
<tr>
<td>6</td>
<td>Academic Officer / Asst Registrar</td>
</tr>
<tr>
<td>7</td>
<td>The Sankara Nethralaya Academy</td>
</tr>
<tr>
<td>8</td>
<td>No 9, Vanagaram – Ambattur Road</td>
</tr>
<tr>
<td>9</td>
<td>Ayanambakkam, Chennai – 600 095</td>
</tr>
<tr>
<td>10</td>
<td>Ph No : 044 4908 6000</td>
</tr>
<tr>
<td></td>
<td>Fax No : 044 2825 4180</td>
</tr>
<tr>
<td></td>
<td>E – Mail : <a href="mailto:mahali@snmail.org">mahali@snmail.org</a></td>
</tr>
</tbody>
</table>

### Optometry - Short term / Certificate Courses

<table>
<thead>
<tr>
<th>S No</th>
<th>Course details like:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Certificate Course in Retinal Diagnosis – 2 weeks</td>
</tr>
<tr>
<td>2</td>
<td>Certificate Course in Glaucoma Diagnosis – 2 weeks</td>
</tr>
<tr>
<td>3</td>
<td>Certificate Course in Corneal Diagnosis – 2 weeks</td>
</tr>
<tr>
<td>4</td>
<td>Certificate Course in Low Vision Aids – 3 months</td>
</tr>
<tr>
<td>5</td>
<td>Certificate Course in Binocular Vision &amp; Vision Therapy</td>
</tr>
<tr>
<td>6</td>
<td>Certificate Course in Clinical Optometry – 3 months</td>
</tr>
<tr>
<td>7</td>
<td>Fellowship in Low Vision Aids – 6 months</td>
</tr>
<tr>
<td>8</td>
<td>Fellowship in Contact Lens – 6 months</td>
</tr>
<tr>
<td>9</td>
<td>Fellowship in Binocular Vision &amp; Vision Therapy – 6 months</td>
</tr>
<tr>
<td>10</td>
<td>Fellowship in British Dispensing Opticians (FBDO) – 8 months</td>
</tr>
</tbody>
</table>
Now, Download & Read INSIGHT in your iPad, tablet and mobile

Visit http://www.sankaranethralaya.org/insight.html

insight
The scientific journal of MEDICAL & VISION RESEARCH FOUNDATION